1. Home
  2. CELU vs ATNM Comparison

CELU vs ATNM Comparison

Compare CELU & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Celularity Inc.

CELU

Celularity Inc.

HOLD

Current Price

$1.96

Market Cap

56.7M

Sector

Health Care

ML Signal

HOLD

Logo Actinium Pharmaceuticals Inc. (Delaware)

ATNM

Actinium Pharmaceuticals Inc. (Delaware)

HOLD

Current Price

$1.42

Market Cap

50.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CELU
ATNM
Founded
2016
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
56.7M
50.2M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
CELU
ATNM
Price
$1.96
$1.42
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$6.00
$4.00
AVG Volume (30 Days)
65.1K
200.1K
Earning Date
11-14-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$40,578,000.00
$90,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$76.00
$42,943.57
P/E Ratio
N/A
N/A
Revenue Growth
N/A
11.11
52 Week Low
$1.00
$1.03
52 Week High
$4.35
$2.41

Technical Indicators

Market Signals
Indicator
CELU
ATNM
Relative Strength Index (RSI) 55.41 52.42
Support Level $1.62 $1.33
Resistance Level $2.18 $1.54
Average True Range (ATR) 0.14 0.10
MACD 0.04 0.02
Stochastic Oscillator 60.76 51.43

Price Performance

Historical Comparison
CELU
ATNM

About CELU Celularity Inc.

Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.

About ATNM Actinium Pharmaceuticals Inc. (Delaware)

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.

Share on Social Networks: